Free Trial
NASDAQ:ARCT

Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

Arcturus Therapeutics logo
$17.30 +0.01 (+0.06%)
Closing price 04:00 PM Eastern
Extended Trading
$17.74 +0.44 (+2.54%)
As of 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arcturus Therapeutics Stock (NASDAQ:ARCT)

Key Stats

Today's Range
$17.00
$18.32
50-Day Range
$11.39
$19.48
52-Week Range
$8.04
$25.88
Volume
559,685 shs
Average Volume
727,224 shs
Market Capitalization
$469.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.57
Consensus Rating
Buy

Company Overview

Arcturus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

ARCT MarketRank™: 

Arcturus Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 475th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arcturus Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Arcturus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.22) to ($0.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arcturus Therapeutics is -7.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arcturus Therapeutics is -7.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arcturus Therapeutics has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Arcturus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    17.60% of the float of Arcturus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcturus Therapeutics has a short interest ratio ("days to cover") of 9.5.
  • Change versus previous month

    Short interest in Arcturus Therapeutics has recently decreased by 2.46%, indicating that investor sentiment is improving.
  • Dividend Yield

    Arcturus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Arcturus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.60% of the float of Arcturus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcturus Therapeutics has a short interest ratio ("days to cover") of 9.5.
  • Change versus previous month

    Short interest in Arcturus Therapeutics has recently decreased by 2.46%, indicating that investor sentiment is improving.
  • News Sentiment

    Arcturus Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    9 people have searched for ARCT on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.60% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arcturus Therapeutics' insider trading history.
Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARCT Stock News Headlines

Arcturus Therapeutics to Attend Upcoming Investor Conferences
Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
See More Headlines

ARCT Stock Analysis - Frequently Asked Questions

Arcturus Therapeutics' stock was trading at $16.97 on January 1st, 2025. Since then, ARCT stock has increased by 1.9% and is now trading at $17.30.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its quarterly earnings results on Monday, August, 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.11) by $0.77. The biotechnology company had revenue of $28.30 million for the quarter, compared to analyst estimates of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative trailing twelve-month return on equity of 24.87%.
Read the conference call transcript
.

Arcturus Therapeutics' top institutional investors include Sumitomo Mitsui Trust Group Inc. (6.76%), Nikko Asset Management Americas Inc. (6.74%), ARK Investment Management LLC (6.32%) and Geode Capital Management LLC (2.24%). Insiders that own company stock include Pad Chivukula, Magda Marquet and Keith C Kummerfeld.
View institutional ownership trends
.

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/11/2025
Today
8/28/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARCT
CIK
1410997
Fax
N/A
Employees
180
Year Founded
N/A

Price Target and Rating

High Price Target
$66.00
Low Price Target
$35.00
Potential Upside/Downside
+192.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$80.94 million
Net Margins
-49.26%
Pretax Margin
-49.44%
Return on Equity
-24.87%
Return on Assets
-17.75%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.90
Quick Ratio
5.90

Sales & Book Value

Annual Sales
$152.31 million
Price / Sales
3.08
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.51 per share
Price / Book
2.03

Miscellaneous

Outstanding Shares
27,160,000
Free Float
22,647,000
Market Cap
$469.87 million
Optionable
Optionable
Beta
2.26

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ARCT) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners